FDA's Generic Drugs Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Agenda for the panel's Jan. 11-12 meeting includes a discussion of issues related to in vitro dissolution testing of immediate-release and extended-release solid oral dosage forms and its relationship to in vivo bioavailability and bioequivalence. The meeting will begin at 8 a.m. on both days in conference rooms D & E of FDA's Parklawn Building